SLC5A2 and obesity disorder: If albuminuria persists despite maximally tolerated RAAS blockade and SGLT2 inhibition, consider adding a non-steroidal MRA. Consider a GLP-1 receptor agonist in patients with obesity or high cardiovascular risk.